PDCD1 and non-small cell lung carcinoma: Since weekly nab-paclitaxel plus cisplatin is considered promising as a base regimen in combination with ICIs, we would like to conduct a clinical trial of anti-PD-1/−PD-L1 antibodies combined with weekly nab-paclitaxel plus cisplatin for NSCLC in the future.